Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
08 nov. 2021 09h00 HE
|
Celsion CORP
Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
08 nov. 2021 08h30 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
15 oct. 2021 09h00 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion Corporation Announces Oral Presentation at International Vaccines Congress
12 oct. 2021 09h00 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion’s Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion...
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews
11 oct. 2021 09h00 HE
|
Celsion CORP
Investigator-Sponsored Research with ThermoDox® Continues in Multiple Indications New Support for ThermoDox®’s Potential from the National Institutes of Health under a Cooperative Research and...
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
05 oct. 2021 09h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
12 août 2021 08h00 HE
|
Celsion CORP
Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12,...
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
05 août 2021 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
29 juil. 2021 10h00 HE
|
Celsion CORP
Data show dose-dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response...
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
15 juil. 2021 08h00 HE
|
Celsion CORP
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 ...